Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pseudoephedrine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 3/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 3/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 2/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | RGS12 | O14924 | 1/20 | 1.00 |
| ▸ | GLA | P06280 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | PKM | P14618 | 1/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | ALOX12 | P18054 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | HTR2A | P28223 | 1/20 | 1.00 |
| ▸ | THPO | P40225 | 1/20 | 1.00 |
| ▸ | GNAI1 | P63096 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.96 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Racephedrine SCHEMBL2633794 | 1.00 | CYP2D6 (1.00) | CYP2D6ADRA2CCYP3A4CYP2C19CHRM2 | |
| Ephedrine SCHEMBL4785 | 1.00 | CYP2D6 (1.00) | CYP2D6ADRA2CCYP3A4CYP2C19CHRM2 | |
| Ephedrine SCHEMBL30411556 | 1.00 | CYP2D6 (1.00) | CYP2D6ADRA2CCYP3A4CYP2C19CHRM2 | |
| Racephedrine SCHEMBL8098202 | 1.00 | CYP2D6 (1.00) | CYP2D6ADRA2CCYP3A4CYP2C19CHRM2 | |
| Racephedrine SCHEMBL11906521 | 1.00 | CYP2D6 (1.00) | CYP2D6ADRA2CCYP3A4CYP2C19CHRM2 | |
| Racephedrine SCHEMBL4786 | 1.00 | CYP2D6 (1.00) | CYP2D6ADRA2CCYP3A4CYP2C19CHRM2 | |
| Ephedrine SCHEMBL4731265 | 1.00 | CYP2D6 (1.00) | CYP2D6ADRA2CCYP3A4CYP2C19CHRM2 | |
| Racephedrine SCHEMBL12573578 | 1.00 | CYP2D6 (1.00) | CYP2D6ADRA2CCYP3A4CYP2C19CHRM2 | |
| Racephedrine SCHEMBL4369 | 1.00 | CYP2D6 (1.00) | CYP2D6ADRA2CCYP3A4CYP2C19CHRM2 | |
| Racephedrine SCHEMBL420779 | 1.00 | CYP2D6 (1.00) | CYP2D6ADRA2CCYP3A4CYP2C19CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 29566 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3607938-B1 | PHARMACEUTICAL COMPOSITION | SOVIC BRKICIC LJILJANA (HR) | 2026-05-27 | — | — | EP | claimed |
| CN-122094963-A | Cardioprotective lipids and methods of use | — | 2026-05-26 | — | — | CN | claimed |
| WO-2026104388-A1 | DECONGESTANT CONTROLLED RELEASE DRUG DELIVERY SYSTEM | FAES FARMA, S.A. (ES) | 2026-05-21 | — | — | WO | claimed |
| US-12631647-B2 | Lock and key templation of molecularly imprinted polymer for small molecule recognition | Genesee Valley Innovations, LLC (US) | 2026-05-19 | — | — | US | claimed |
| US-12629422-B2 | Agave syrup formulation or suspension for active pharmaceutical agents | GENEXA INC. (US) | 2026-05-19 | — | — | US | claimed |
| EP-4736841-A1 | A MUCOADHESIVE LAYER FOR BUCCAL ADMINISTRATION OF AN ACTIVE PHARMACEUTICAL INGREDIENT | IQ medical GmbH (DE) | 2026-05-06 | — | — | EP | claimed |
| EP-4734952-A1 | ORAL TABLET WITH IMPROVED UNIFORMITY OF CONTENT OF ACTIVES | Fertin Pharma A/S (DK) | 2026-05-06 | — | — | EP | claimed |
| US-12617809-B2 | Cardioprotective lipid and method of use | SIGNPATH PHARMA, INC. (US) | 2026-05-05 | — | — | US | claimed |
| EP-4731194-A1 | MATERIALS AND METHODS FOR MITIGATING THE PRESENCE OF NITROSAMINES IN PACKAGING USING AN ACTIVE AGENT | CSP Technologies, Inc. (US) | 2026-04-29 | — | — | EP | claimed |
| US-20260108531-A1 | Methods of Treating Hypogonadism with Transnasal Testosterone Bio-adhesive Gel Formulations in Males with Allergic Rhinitis and Methods for Preventing an Allergic Rhinitis Event | ACERUS BIOPHARMA INC (CA) | 2026-04-23 | — | — | US | claimed |
| US-4552899-A | ANTITUSSIVE AGENTS | ANALGESIC ASSOCIATES (US) | 1985-11-12 | — | — | US | claimed |
| WO-1985004589-A1 | COUGH/COLD MIXTURES COMPRISING NON-STEROIDAL ANTI-INFLAMMATORY DRUGS | SUNSHINE ABRAHAM | 1985-10-24 | — | — | WO | claimed |
| EP-0153836-A2 | Dry, water-foamable pharmaceutical compositions | HEALTH PRODUCTS DEVELOPMENT INC. (US) | 1985-09-04 | — | — | EP | claimed |
| EP-0132472-A1 | Medicated products containing a magnesium trisilicate adsorbent with a medicament drug adsorbed thereon | WARNER-LAMBERT COMPANY (US) | 1985-02-13 | — | — | EP | claimed |
| US-4369172-A | Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose | FOREST LABORATORIES INC. (US) | 1983-01-18 | — | — | US | claimed |
| US-4277420-A | Ephedrine and pseudoephedrine precursors | MONSANTO COMPANY (US) | 1981-07-07 | — | — | US | claimed |
| US-4260596-A | Edible unit dosage form consisting of outer mannitol shell and inner liquid or gel center and method for manufacturing the same | BRISTOL-MYERS COMPANY (US) | 1981-04-07 | — | — | US | claimed |
| US-4221778-A | ION EXCHANGE RESINS, ANTISWELLING AGENTS | PENNWALT CORPORATION (US) | 1980-09-09 | — | — | US | claimed |
| US-4205060-A | Microcapsules containing medicament-polymer salt having a water-insoluble polymer sheath, their production and their use | PENNWALT CORPORATION (US) | 1980-05-27 | — | — | US | claimed |
| US-RE29875-E | THEOPHYLLINE SOLUBILIZED BY GLYCERYL GUAIACOLATE, POTASSIUM GUAIACOL SULFONATE OR GUAIACOL | MEAD JOHNSON & COMPANY (US) | 1979-01-02 | — | — | US | claimed |